Abstract
Antibody-based therapeutics are a fast-growing sector in the pharmaceutical industry. One large contributor to the high cost associated with development of new antibody therapeutics is the separation and purification process, which is currently iterative and empirical. More information about how antibodies interact with stationary phases would be helpful in improving the process. I will discuss our recent efforts to track single, fluorescently labeled antibodies as they interact with an ion-exchange stationary phase.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
